Brokerages predict that Aptevo Therapeutics Inc (NASDAQ:APVO) will post earnings of ($0.32) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Aptevo Therapeutics’ earnings. Aptevo Therapeutics posted earnings of $0.01 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 3,300%. The business is expected to issue its next quarterly earnings report on Friday, March 30th.

According to Zacks, analysts expect that Aptevo Therapeutics will report full-year earnings of $0.43 per share for the current year. For the next fiscal year, analysts anticipate that the company will post earnings of ($2.69) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Aptevo Therapeutics.

A number of analysts have recently issued reports on APVO shares. ValuEngine upgraded Aptevo Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, October 12th. Piper Jaffray Companies reiterated an “overweight” rating and set a $6.00 price target on shares of Aptevo Therapeutics in a research report on Thursday, October 5th.

Shares of Aptevo Therapeutics (NASDAQ APVO) traded down $0.05 on Friday, hitting $4.47. The stock had a trading volume of 114,700 shares, compared to its average volume of 231,238. The company has a market cap of $94.07 and a P/E ratio of -2.46. The company has a current ratio of 7.76, a quick ratio of 7.67 and a debt-to-equity ratio of 0.19. Aptevo Therapeutics has a 12-month low of $1.15 and a 12-month high of $4.85.

In other news, VP Randy Joe Maddux bought 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The stock was bought at an average price of $2.76 per share, for a total transaction of $69,000.00. Following the transaction, the vice president now directly owns 25,000 shares of the company’s stock, valued at approximately $69,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 15.60% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc lifted its position in Aptevo Therapeutics by 11,751.3% in the 2nd quarter. Legal & General Group Plc now owns 393,701 shares of the biotechnology company’s stock worth $815,000 after buying an additional 390,379 shares during the last quarter. Precept Management LLC bought a new stake in Aptevo Therapeutics in the 2nd quarter worth approximately $1,210,000. Finally, Dimensional Fund Advisors LP lifted its position in Aptevo Therapeutics by 8.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,056,729 shares of the biotechnology company’s stock worth $2,187,000 after buying an additional 78,109 shares during the last quarter. Institutional investors own 32.13% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.watchlistnews.com/aptevo-therapeutics-inc-apvo-expected-to-post-earnings-of-0-32-per-share/1804499.html.

About Aptevo Therapeutics

Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.

Get a free copy of the Zacks research report on Aptevo Therapeutics (APVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.